
ARCUS OVERVIEW

NYSE: RCUS



Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer



HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF2a, A2a/2b, AXL



Targets: TIGIT. PD-1, CD39

new molecules advancing into clinic each year



Accelerated

P 1/2 signalseeking & platform studies

DIVERSE PIPELINE WITH MULTIPLE "SHOTS ON GOAL"

Different molecules in clinic



Registrational Phase 3 trials evaluating a differentiated, Fc-silent anti-TIGIT antibody domvanalimab

24-36

Months for potential approval & revenue generation



Addressable market opportunity in the U.S. based on expected drug treatable patient population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

- Holds ~19% equity stake in Arcus
- 50/50 Cost-sharing for optioned programs
- Co-development / co-commercialization in the U.S.







STRONG FINANCIAL POSITION & CASH **RUNWAY WITH FUNDING INTO 2026**




& marketable securities as of 9/30/2023

HQ & RESEARCH CAMPUSES IN BAY AREA







This summary is provided as of 9/30/23. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding into 2026, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com